Additionally, despite recent progress with CFTR modulators for cystic fibrosis, the continued development of new mucolytic, anti-inflammatory, and anti-infective therapies remains crucial, particularly for patients with advanced stages of lung disease [20]. This evidence concerns the gene CFTR and cystic fibrosis.